Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Goodwill & Intangibles (2020 - 2025)

Cytek Biosciences' Goodwill & Intangibles history spans 6 years, with the latest figure at $33.5 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 8.9% year-over-year to $33.5 million; the TTM value through Dec 2025 reached $33.5 million, down 8.9%, while the annual FY2025 figure was $33.5 million, 8.9% down from the prior year.
  • Goodwill & Intangibles reached $33.5 million in Q4 2025 per CTKB's latest filing, down from $34.4 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $43.8 million in Q1 2023 to a low of $809000.0 in Q2 2021.
  • Average Goodwill & Intangibles over 5 years is $27.9 million, with a median of $35.3 million recorded in 2025.
  • Peak YoY movement for Goodwill & Intangibles: skyrocketed 1884.4% in 2021, then fell 12.26% in 2024.
  • A 5-year view of Goodwill & Intangibles shows it stood at $14.9 million in 2021, then dropped by 2.74% to $14.5 million in 2022, then surged by 171.27% to $39.3 million in 2023, then fell by 6.31% to $36.8 million in 2024, then fell by 8.9% to $33.5 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Goodwill & Intangibles are $33.5 million (Q4 2025), $34.4 million (Q3 2025), and $35.3 million (Q2 2025).